Sign in
ADVM Stock Price, Chart, Stats & News
Adverum Biotechnologies, Inc.
Save
Adverum Biotechnologies, Inc. (ADVM) does not currently pay a dividend.
96.26M
Market cap
–
Current P/E
–
Forward P/E
ADVM chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -282.31% |
ROE | -3844.85% |
D/E | -1.60x |
Interest coverage ratio | – |
ADVM valuation
P/E | – |
P/S | – |
P/B | -1.84x |
P/CF | -0.74x |
P/FCF | -0.70x |
P/OCF | -0.74x |
PEG | 0.05x |
EV multiple | -0.16x |
About
Adverum Biotechnologies, Inc. is a clinical-phase biotechnology firm primarily engaged in discovering and advancing gene therapies. The company's mission is to create innovative treatments for various eye-related conditions and uncommon illnesses. Its flagship experimental gene therapy, ADVM-022, is a potential therapy administered through a single injection into the vitreous humor of the eye.
Similar securities
Based on sector and market capitalization
Report issue